drugset
drugset / Trial / NCT06171113

A Study to Investigate the Safety of GSK4024484 in Healthy Adult Participants

NCT06171113 ↗

Phase 1 Completed 123 enrolled GlaxoSmithKline
RandomizedSequentialQuadruple-blindTreatment

Summary

The primary purpose of the study is to characterise the safety of GSK4024484 in healthy participants within a controlled pharmacokinetic (PK) range, and the effect of food on the study intervention.

Timeline

Start
2023-12-11
Primary completion
2026-06-16
Completion
2026-06-16

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK4024484C Unknown 6 mg Oral
Subject GSK4024484C Unknown 12 mg Oral
Subject GSK4024484C Unknown 24 mg Oral
Subject GSK4024484C Unknown 48 mg Oral
Subject GSK4024484C Unknown 96 mg Oral
Subject GSK4024484C Unknown 150 mg Oral
Subject GSK4024484C Unknown 192 mg Oral
Subject GSK4024484C Unknown 300 mg Oral
Subject GSK4024484C Unknown 400 mg Oral

Indications

Plasmodium falciparum malaria